| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 355 | 2021 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 298 | 2020 |
| Real-world experience with caplacizumab in the management of acute TTP T Dutt, RJ Shaw, M Stubbs, J Yong, B Bailiff, T Cranfield, MP Crowley, ... Blood, The Journal of the American Society of Hematology 137 (13), 1731-1740, 2021 | 128 | 2021 |
| Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy TA Eyre, HS Walter, S Iyengar, G Follows, M Cross, CP Fox, A Hodson, ... Haematologica 104 (2), e68, 2019 | 125 | 2019 |
| Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 107 | 2020 |
| Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients UKCLL Forum haematologica 101 (12), 1563, 2016 | 104 | 2016 |
| Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study JJ Castillo, G Itchaki, J Paludo, M Varettoni, C Buske, TA Eyre, JC Chavez, ... Blood, The Journal of the American Society of Hematology 133 (4), 299-305, 2019 | 89 | 2019 |
| Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice LE Roeker, CP Fox, TA Eyre, DM Brander, JN Allan, SJ Schuster, ... Clinical Cancer Research 25 (14), 4264-4270, 2019 | 75 | 2019 |
| Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents LE Roeker, P Dreger, JR Brown, OB Lahoud, TA Eyre, DM Brander, ... Blood advances 4 (16), 3977-3989, 2020 | 71 | 2020 |
| Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia J Klintman, N Appleby, B Stamatopoulos, K Ridout, TA Eyre, P Robbe, ... Blood, The Journal of the American Society of Hematology 137 (20), 2800-2816, 2021 | 69 | 2021 |
| Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCR inhibitor setting: a UK wide analysis TA Eyre, AA Kirkwood, S Gohill, G Follows, R Walewska, H Walter, ... British journal of haematology 185 (4), 656-669, 2019 | 69 | 2019 |
| Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy … TA Eyre, F Djebbari, AA Kirkwood, GP Collins Haematologica 105 (7), 1914, 2020 | 65 | 2020 |
| NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome TA Eyre, R Clifford, A Bloor, L Boyle, C Roberts, M Cabes, GP Collins, ... British journal of haematology 175 (1), 43-54, 2016 | 65 | 2016 |
| Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy R McCulloch, C Visco, TA Eyre, R Frewin, N Phillips, DL Tucker, ... British journal of haematology 189 (4), 684-688, 2020 | 62 | 2020 |
| Multiple myeloma in the very elderly patient: challenges and solutions J Willan, TA Eyre, F Sharpley, C Watson, AJ King, K Ramasamy Clinical interventions in aging, 423-435, 2016 | 61 | 2016 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 59 | 2021 |
| Anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease TA Eyre, D Khan, GW Hall, GP Collins European journal of haematology 93 (6), 455-468, 2014 | 59 | 2014 |
| Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is … TA Eyre, AA Kirkwood, J Wolf, C Hildyard, C Mercer, H Plaschkes, ... British journal of haematology 187 (2), 185-194, 2019 | 56 | 2019 |
| Time now to TORC the TORC? New developments in m TOR pathway inhibition in lymphoid malignancies TA Eyre, GP Collins, AH Goldstone, K Cwynarski British journal of haematology 166 (3), 336-351, 2014 | 54 | 2014 |
| Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients MR Wilson, TA Eyre, AA Kirkwood, N Wong Doo, C Soussain, S Choquet, ... Blood, The Journal of the American Society of Hematology 139 (16), 2499-2511, 2022 | 53 | 2022 |
Graham CollinsOxfordDirección de correo verificada de ouh.nhs.uk
